Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
32 participants
INTERVENTIONAL
2026-02-28
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
NCT04485481
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
NCT03491748
A Study of CPTX2309 in Healthy Participants
NCT06917742
Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers
NCT06780124
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers
NCT01281774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
STLX-2012
Single ascending doses of STLX-2012
STLX-2012
STLX-2012 IV
Placebo
Placebo
Placebo
Placebo arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STLX-2012
STLX-2012 IV
Placebo
Placebo arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index of 18-32 kg/m\^2, inclusive
* Healthy as determined by the investigator
* Adequate hepatic and renal function
* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
* Male participants and females of childbearing potential must agree to use an effective method of contraception for 30 days after the last dose of STLX-2012
Exclusion Criteria
* Positive urine drug screen or alcohol breath test
* Neutropenia, defined as neutrophil count \<2.0 x 10\^9/L
* History of allergic reaction requiring treatment or anaphylactic reactions to any therapeutic drug.
* Previous treatment with an IL-1RAP monoclonal antibody
* History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, inflammatory, or allergic disease (excluding mild seasonal allergies)
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stelexis BioSciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network Brisbane
Brisbane, Queensland, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STLX-2012-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.